Gilead CSO, Other Executives, Departing Company as CEO Continues to Reshape C-Suite

ALEX KEOWN | July 17, 2019 | 53 views

Gilead Sciences is seeing a significant change in its executive leadership team as multiple longtime employees are heading out the door as new Chief Executive Officer Daniel O’Day continues to shape the lineup of his lieutenants.

Spotlight

LI-COR Biosciences

At LI-COR Biosciences our mission is to help scientists find better answers to their questions. We believe that data of exceptional quality provides answers with exceptional clarity. In turn, the results help improve the world where we live and the quality of individual’s lives. More than 30,000 customers in more than 100 countries are using LI-COR research solutions on a daily basis. Their research includes cutting edge discovery in the areas of global climate change, drug discovery, environmental and life sciences. Our global team of employees understand that each day our goal is to impact lives. This is realized through a strength-based approach to team building that puts every employee on task to make a difference. Whether it's your first week or your 35th year, your skills and opinions are valued and must contribute to our mission to help improve the world where we live.

OTHER ARTICLES
MEDICAL

Top 10 biotech IPOs in 2019

Article | August 16, 2022

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
RESEARCH

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | July 11, 2022

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More
MEDTECH

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | October 7, 2022

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Selexis Cell Line Development Strategies

Article | February 11, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

Spotlight

LI-COR Biosciences

At LI-COR Biosciences our mission is to help scientists find better answers to their questions. We believe that data of exceptional quality provides answers with exceptional clarity. In turn, the results help improve the world where we live and the quality of individual’s lives. More than 30,000 customers in more than 100 countries are using LI-COR research solutions on a daily basis. Their research includes cutting edge discovery in the areas of global climate change, drug discovery, environmental and life sciences. Our global team of employees understand that each day our goal is to impact lives. This is realized through a strength-based approach to team building that puts every employee on task to make a difference. Whether it's your first week or your 35th year, your skills and opinions are valued and must contribute to our mission to help improve the world where we live.

Related News

Gilead Expands Galapagos Stake, Filgotinib Role, Pipeline Access in 5.1B Dollars R and D Collaboration

Genengnews | July 15, 2019

Gilead Sciences will shell out 5.1 billion dollars to nearly double its minority stake in Galapagos from approximately 12.3% to at least 22% and possibly about 30% through a 10-year global R and D collaboration in which Gilead will expand its role in the companies arthritis candidate filgotinib and co-develop the rest of Galapagos pipeline. “Gilead also gains exclusive access to all current and future compounds in Galapagos’ rich pipeline while Galapagos is able to expand its research activities and build commercial infrastructure,” Gilead Chairman and CEO Daniel O’Day said yesterday in a statement. Galapagos’ pipeline includes six molecules currently in clinical trials, more than 20 preclinical programs, and a drug discovery platform designed to discover and verify novel targets by using disease-related, human primary cell-based assays. In the first major R&D deal under O’Day, who took the company’s helm on March 1, Gilead agreed to pay Galapagos an eye-popping $3.95 billion upfront—more than 12 times the €318 million ($358 million) in revenue generated by Galapagos last year, and 18% of Gilead’s total $22.127 billion in 2018 revenue. Gilead will also make a $1.12 billion equity investment in Galapagos, which will use the proceeds to expand and accelerate its R&D programs, the companies said. The equity investment will consist of a subscription for new Galapagos shares at a price of €140.59 ($158.42) per share, representing a 20% premium to Galapagos’ 30-day, volume-weighted average price.

Read More

Gilead Pledges 2.4 Million Annual Dose Donations of Drug to End HIV in the U.S.

Biospace | May 10, 2019

As part of a national effort from the federal government to combat HIV and prevent future infections, Gilead Sciences announced it will annually donate 2.4 million doses of its HIV treatment Truvada for PrEP to the U.S. Centers for Disease Control and Prevention (CDC) to provide treatment for uninsured Americans. Foster City, Calif.-based Gilead said the donation is among the largest seen in the United States and is part of the company’s ongoing initiative to help ensure that all patients who can benefit from Truvada for PrEP can have access to it. PrEP, which has a list price of $20,000, is used to reduce the risk of HIV infection in individuals who are at higher risk for HIV. It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently.

Read More

Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir

Gilead Sciences | December 08, 2016

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of direct-acting antiviral (DAA)-experienced chronic hepatitis C virus (HCV)-infected patients. The data submitted in the NDA support the use of the regimen for 12 weeks in DAA-experienced patients with genotype 1 to 6 HCV infection without cirrhosis or with compensated cirrhosis.

Read More

Gilead Expands Galapagos Stake, Filgotinib Role, Pipeline Access in 5.1B Dollars R and D Collaboration

Genengnews | July 15, 2019

Gilead Sciences will shell out 5.1 billion dollars to nearly double its minority stake in Galapagos from approximately 12.3% to at least 22% and possibly about 30% through a 10-year global R and D collaboration in which Gilead will expand its role in the companies arthritis candidate filgotinib and co-develop the rest of Galapagos pipeline. “Gilead also gains exclusive access to all current and future compounds in Galapagos’ rich pipeline while Galapagos is able to expand its research activities and build commercial infrastructure,” Gilead Chairman and CEO Daniel O’Day said yesterday in a statement. Galapagos’ pipeline includes six molecules currently in clinical trials, more than 20 preclinical programs, and a drug discovery platform designed to discover and verify novel targets by using disease-related, human primary cell-based assays. In the first major R&D deal under O’Day, who took the company’s helm on March 1, Gilead agreed to pay Galapagos an eye-popping $3.95 billion upfront—more than 12 times the €318 million ($358 million) in revenue generated by Galapagos last year, and 18% of Gilead’s total $22.127 billion in 2018 revenue. Gilead will also make a $1.12 billion equity investment in Galapagos, which will use the proceeds to expand and accelerate its R&D programs, the companies said. The equity investment will consist of a subscription for new Galapagos shares at a price of €140.59 ($158.42) per share, representing a 20% premium to Galapagos’ 30-day, volume-weighted average price.

Read More

Gilead Pledges 2.4 Million Annual Dose Donations of Drug to End HIV in the U.S.

Biospace | May 10, 2019

As part of a national effort from the federal government to combat HIV and prevent future infections, Gilead Sciences announced it will annually donate 2.4 million doses of its HIV treatment Truvada for PrEP to the U.S. Centers for Disease Control and Prevention (CDC) to provide treatment for uninsured Americans. Foster City, Calif.-based Gilead said the donation is among the largest seen in the United States and is part of the company’s ongoing initiative to help ensure that all patients who can benefit from Truvada for PrEP can have access to it. PrEP, which has a list price of $20,000, is used to reduce the risk of HIV infection in individuals who are at higher risk for HIV. It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently.

Read More

Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir

Gilead Sciences | December 08, 2016

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of direct-acting antiviral (DAA)-experienced chronic hepatitis C virus (HCV)-infected patients. The data submitted in the NDA support the use of the regimen for 12 weeks in DAA-experienced patients with genotype 1 to 6 HCV infection without cirrhosis or with compensated cirrhosis.

Read More

Events